TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: As our attempts to address this limitation by restricting Cre activity, inhibiting p53, and/or circumventing clonal competition were unsuccessful, we sought to develop a version of Genome-Shuffle-seq relying on Bxb1 rather than Cre recombinase, as well as to expand our evaluation to include human K562 cells, which derive from a p53-null, chronic myelogenous leukemia.